Transcatheter Aortic Valve Replacement Market to Reach US$ 30.01 Billion by 2035 at 15.2% CAGR, Driven by Improved Clinical Outcomes and Increasing Adoption of Catheter-Based Cardiac Interventions | Exclusive Report by The Insight Partners

The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.

11/12/2026, 4:54 AM • GlobeNewswire

Global Sacral Neuromodulation Market Size, Share, Trends and Forecast 2026-2036: Rechargeable, MRI-Compatible Systems Drive 11.1% CAGR

The global sacral neuromodulation market is estimated at USD 1.37 billion in 2026 and projected to reach USD 3.92 billion by 2036, growing at 11.1% CAGR. Market expansion is driven by rising prevalence of urinary and fecal incontinence, aging populations, and technological advancements in rechargeable and MRI-compatible devices. Key challenges include high procedural costs and complex regulatory requirements. North America leads the market while Asia-Pacific is expected to register the fastest growth.

11/06/2026, 10:58 AM • GlobeNewswire

National Advertising Division to Refer Kendal to Government Agencies and Advertising Platforms for Electing Not to Participate in Compliance Inquiry

The National Advertising Division (NAD) of BBB National Programs will refer Kendal Nutricare Limited to government agencies and advertising platforms for enforcement action after the company refused to participate in a compliance inquiry. This follows a challenge by Abbott Laboratories regarding Kendamil Infant Formula advertising claims about whole milk, breast milk, HMOs, and milk fat content that NAD had previously recommended be discontinued or modified.

11/06/2026, 10:00 AM • GlobeNewswire

Continuous Glucose Monitoring Market in India: USD 452.9 Million Opportunity by 2032 as Digital Diabetes Care Expands, Reports Mordor Intelligence

India's continuous glucose monitoring market is projected to grow at a CAGR of 11.90% from 2027-2032, reaching USD 452.9 million by 2032. The market expansion is driven by growing adoption of sensor-based monitoring, digital healthcare integration, and expanding diabetes management programs. However, high device costs and limited reimbursement coverage remain barriers to wider adoption.

11/03/2026, 2:30 AM • GlobeNewswire

Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy?

Medtronic completed a spinoff of its diabetes segment (MiniMed) and retired 55 million shares without cash expenditure, which will boost future EPS. The company reported strong Q1 FY2027 results with 14% revenue growth and is approaching Dividend King status (49 consecutive years of increases). Despite operational improvements and a reinvigorated pipeline with 50+ FDA approvals, Medtronic trades at a discount to medtech peers.

11/01/2026, 12:21 AM • The Motley Fool

Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact

Boston Scientific (BSX) stock fell 6% after the medical device maker cut its Q4 sales and full-year EPS guidance due to ongoing disruptions from an August cyberattack. The company estimated the eight-day cyberattack cost it 300 basis points in sales growth and $0.07 in adjusted EPS. Management expects a slow recovery with 2027 projected as the trough year, though the stock now trades at a relatively low 13x forward earnings multiple.

10/28/2026, 4:50 PM • The Motley Fool

This Dividend King Just Announced Great News for Investors

Abbott Laboratories reported solid Q3 2026 results with 7% sales growth and 9% higher adjusted EPS. The company announced a significant decision to spin off its struggling nutrition business into a standalone company, which should improve growth prospects. Abbott's core medical device segment, particularly its FreeStyle Libre diabetes care products and recent Exact Sciences acquisition for cancer diagnostics, positions the company well for future growth. As a Dividend King with 50+ consecutive years of dividend increases, Abbott remains attractive for income investors.

10/26/2026, 1:58 PM • The Motley Fool

Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?

The article compares Abbott Laboratories and UnitedHealth Group as healthcare investment options. Abbott, with $44.3B in revenue and a conservative 0.3x debt-to-equity ratio, focuses on medical devices, diagnostics, and pharmaceuticals, with planned growth from the Exact Sciences acquisition and a nutrition business spin-off. UnitedHealth, with $447.6B in revenue but higher leverage at 0.8x debt-to-equity, dominates insurance and healthcare services but faces government policy risks and reputational challenges. The author recommends Abbott for its innovation focus and lower exposure to healthcare cost-control initiatives.

10/24/2026, 1:11 PM • The Motley Fool

Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device

Catheter Precision, a subsidiary of Flyte Aviation (NYSE American: VJET), published a peer-reviewed study in The Journal of Interventional Cardiology demonstrating that its LockeT suture retention device outperforms Abbott's Perclose vascular closure device. The 172-patient study showed LockeT achieved 1.2% access-site complications versus 9.3% for Perclose, with zero device failures compared to 4.7% for Perclose, while maintaining equivalent efficiency in hemostasis and same-day discharge rates.

10/22/2026, 4:54 PM • GlobeNewswire

Abbott: 3 Key Takeaways for Long-Term Investors

Abbott announced plans to spin off its nutrition business into an independent public company, focusing on higher-margin medical technologies and diagnostics. The company reported 7% year-over-year comparable sales growth in Q3 2026, with cancer diagnostics sales up 14% driven by Cologuard and new blood-based colorectal cancer screening tests. Pulsed field ablation technology is accelerating growth in electrophysiology, positioning Abbott for accelerated growth beyond historical rates.

10/21/2026, 4:15 PM • The Motley Fool

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale

The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, expanding at a 20.2% CAGR. Growth is driven by rising chronic disease management demand, expanding reimbursement coverage, and maturing wearable sensor technology, enabling a shift from episodic facility-centered care to continuous connected care models.

10/21/2026, 5:00 AM • GlobeNewswire

Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio.

With the Federal Reserve likely to maintain or raise interest rates through the end of 2026, dividend stocks like AbbVie are positioned to perform well. AbbVie, a pharmaceutical company with over 50 years of dividend increases, offers resilience in a high-rate environment due to its strong balance sheet, fixed-rate debt, and non-rate-sensitive business model.

10/20/2026, 11:45 AM • The Motley Fool

3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case.

Three Wall Street analysts have $500 price targets for Intuitive Surgical, citing strong growth in robot-assisted surgery procedures and the rollout of the da Vinci 5 platform. The company benefits from a recurring revenue model through instruments and accessories, with procedures growing 15% year-over-year. However, the stock's high P/E ratio of ~49 leaves limited room for disappointment.

10/19/2026, 9:30 AM • The Motley Fool

Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy.

Ken Griffin's Citadel significantly increased positions in healthcare stocks during Q2, boosting AbbVie by 546%, Abbott Laboratories by 349%, and Eli Lilly by 291%. The moves suggest Griffin is seeking defensive, dividend-yielding stocks amid anticipated market volatility. AbbVie, a Dividend King with 54 consecutive years of dividend increases, is highlighted as a strong buy with attractive valuation and solid earnings growth.

10/18/2026, 8:15 AM • The Motley Fool

Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle

AbbVie is positioned as a reliable dividend stock that avoids high-yield trap characteristics. With 54 consecutive years of dividend increases, strong free cash flow generation, fixed-rate debt, and blockbuster drugs Skyrizi and Rinvoq generating over $7.5 billion quarterly, AbbVie maintains Dividend King status regardless of interest rate cycles. The company's robust pipeline of 90 clinical programs provides future revenue stability.

10/17/2026, 4:44 AM • The Motley Fool